Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 4:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 128 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Muscle Invasive Bladder Urothelial Carcinoma Clear all
Completed Phase 1Phase 2 Interventional Results available

Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer

NCT03081858
View directory record Official record
Conditions
Bladder Cancer Cell Transitional, Non-Muscle Invasive Bladder Cancer, Bladder Cancer, Urinary Bladder, Transitional Cell Carcinoma of the Bladder, Urinary Bladder Neoplasms, Urologic Neoplasms, Urogenital Neoplasms, Urinary Bladder Diseases, Urologic Diseases
Interventions
TSD-001
Drug
Lead sponsor
Lipac Oncology LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
5
States / cities
Tucson, Arizona • Bakersfield, California • Los Angeles, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Sep 28, 2026, 4:52 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

NCT06111235
View directory record Official record
Conditions
Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
Interventions
Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside
Drug · Other
Lead sponsor
CG Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
90
States / cities
Homewood, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 28, 2026, 4:52 AM EDT
Recruiting Phase 1 Interventional

FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3

NCT05614739
View directory record Official record
Conditions
Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms
Interventions
Vepugratinib, Pembrolizumab, enfortumab vedotin, Trastuzumab Deruxtecan, Midazolam, Digoxin, Rosuvastatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
677 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
41
States / cities
Tucson, Arizona • Duarte, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Phase 2 Interventional Results available

Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer

NCT04496219
View directory record Official record
Conditions
Bladder Urothelial Carcinoma In Situ, Recurrent Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8, Superficial Bladder Urothelial Carcinoma
Interventions
Acupuncture Therapy, BCG Solution, Best Practice, Quality-of-Life Assessment, Questionnaire Administration
Device · Biological · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 1, 2024 · Synced Sep 28, 2026, 4:52 AM EDT
Recruiting No phase listed Observational

Pan-tumor MRD Study

NCT06605404
View directory record Official record
Conditions
Muscle Invasive Bladder Urothelial Carcinoma, Esophageal Cancer, Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma, Melanoma (Skin Cancer), NSCLC (Non-small Cell Lung Cancer), Pancreatic (Exocrine Only), Mix of Solid Tumors (MOST)
Interventions
blood and tissue samples, blood and tissue samples
Diagnostic Test · Other
Lead sponsor
Paradigm Health
Industry
Eligibility
18 Years and older
Enrollment
1,350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
47
States / cities
Birmingham, Alabama • Bullhead City, Arizona • Casa Grande, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 28, 2026, 4:52 AM EDT
Active, not recruiting Phase 1 Interventional

Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBC

NCT05768347
View directory record Official record
Conditions
Urothelial Carcinoma, Non-Invasive Bladder Urothelial Carcinoma
Interventions
Adoptive Cell Therapy with Tumor-infiltrating Lymphocytes (TIL)
Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Sep 28, 2026, 4:52 AM EDT
Recruiting Phase 2 Interventional

Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy

NCT06263153
View directory record Official record
Conditions
Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Durvalumab, Futibatinib, Magnetic Resonance Imaging, Radical Cystectomy
Procedure · Biological · Drug
Lead sponsor
Yuanquan Yang
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Ann Arbor, Michigan • Cleveland, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 28, 2026, 4:52 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer

NCT01625260
View directory record Official record
Conditions
Non-muscle Invasive Bladder Cancer
Interventions
ALT-801, Gemcitabine
Biological · Drug
Lead sponsor
Altor BioScience
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
5
States / cities
Birmingham, Alabama • Sacramento, California • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2024 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Phase 1 Interventional

Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer

NCT02722538
View directory record Official record
Conditions
Urinary Bladder Cancer
Interventions
Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200
Drug
Lead sponsor
Taris Biomedical LLC
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
5
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2023 · Synced Sep 28, 2026, 4:52 AM EDT
Recruiting No phase listed Observational

Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE)

NCT06396533
View directory record Official record
Conditions
Urothelial Carcinoma, Muscle Invasive Bladder Urothelial Carcinoma, Non-Muscle Invasive Bladder Urothelial Carcinoma
Interventions
Not listed
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Omaha, Nebraska • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Sep 28, 2026, 4:52 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder

NCT02202772
View directory record Official record
Conditions
Urothelial Carcinoma of the Urinary Bladder
Interventions
Cabazitaxel, Gemcitabine, Cisplatin
Drug
Lead sponsor
Guarionex J. Decastro
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Sep 28, 2026, 4:52 AM EDT
Withdrawn Phase 1 Interventional

Talimogene Laherparepvec in Treating Patients With Non-Muscle Invasive Bladder Transitional Cell Carcinoma

NCT03430687
View directory record Official record
Conditions
Stage 0 Bladder Urothelial Carcinoma AJCC v6 and v7, Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7, Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7, Stage I Bladder Urothelial Carcinoma AJCC v6 and v7
Interventions
Laboratory Biomarker Analysis, Talimogene Laherparepvec
Other · Biological
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Sep 28, 2026, 4:52 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

NCT02138734
View directory record Official record
Conditions
Non-muscle Invasive Bladder Cancer
Interventions
BCG (50mg/instillation) + N-803 (400 μg/instillation), BCG (50mg/instillation)
Biological
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2039
U.S. locations
72
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 28, 2026, 4:52 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)

NCT06305767
View directory record Official record
Conditions
Bladder Cancer
Interventions
Pembrolizumab, Intismeran autogene, Placebo, Enfortumab Vedotin, Surgery (RC plus PLND)
Biological · Other · Procedure
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
10
States / cities
Los Angeles, California • Orlando, Florida • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Phase 1 Interventional

A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

NCT05375903
View directory record Official record
Conditions
Non-muscle Invasive Bladder Cancer, NMIBC, Carcinoma in Situ of Bladder, Bladder Cancer, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent
Interventions
UGN-301, UGN-201, Gemcitabine
Drug
Lead sponsor
UroGen Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
7
States / cities
Little Rock, Arkansas • Los Angeles, California • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Sep 28, 2026, 4:52 AM EDT
Recruiting Phase 2Phase 3 Interventional

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

NCT05987241
View directory record Official record
Conditions
Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma, Muscle Invasive Ureter Urothelial Carcinoma, Muscle Invasive Urethral Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage IV Bladder Urothelial Carcinoma AJCC v7
Interventions
Biospecimen Collection, cfDNA or ctDNA Measurement, Computed Tomography, Cystoscopy, Magnetic Resonance Imaging, Nivolumab, Questionnaire Administration, Relatlimab
Procedure · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
992 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
491
States / cities
Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 371 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Sep 28, 2026, 4:52 AM EDT
Active, not recruiting Phase 2 Interventional

Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]

NCT03504163
View directory record Official record
Conditions
Bladder Cancer
Interventions
Pembrolizumab (MK-3475), Bacillus Calmette-Guérin (BCG)
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 28, 2026, 4:52 AM EDT
Not listed Phase 1 Interventional

Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure

NCT00109655
View directory record Official record
Conditions
Carcinoma, Transitional Cell, Bladder Neoplasms
Interventions
Oncolytic adenovirus (serotype 5) - CG0070
Biological
Lead sponsor
Cell Genesys
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
8
States / cities
Phoenix, Arizona • San Francisco, California • Billings, Montana + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2008 · Synced Sep 28, 2026, 4:52 AM EDT
Active, not recruiting Phase 3 Interventional

S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer

NCT03091660
View directory record Official record
Conditions
Stage 0 Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Urothelial Carcinoma
Interventions
BCG Solution, BCG Tokyo-172 Strain Solution, BCG Tokyo-172 Strain Vaccine, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
174
States / cities
Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 111 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 28, 2026, 4:52 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer

NCT02989584
View directory record Official record
Conditions
Bladder Cancer, Metastatic Bladder Cancer, Urothelial Carcinoma
Interventions
Atezolizumab, Gemcitabine, Cisplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
11
States / cities
Hartford, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Phase 2 Interventional Results available

Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer

NCT03617913
View directory record Official record
Conditions
Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Stage II Bladder Cancer AJCC v8, Stage II Renal Pelvis Cancer AJCC v8, Stage II Ureter Cancer AJCC v8, Stage II Urethral Cancer AJCC v8, Stage III Bladder Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Stage IIIB Bladder Cancer AJCC v8, Urethral Urothelial Carcinoma
Interventions
Avelumab, Cisplatin, Fluorouracil, Mitomycin, Quality-of-Life Assessment, Radiation Therapy
Drug · Other · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 5, 2023 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Phase 2 Interventional Results available

A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder

NCT04919512
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
TAR-200, Cetrelimab
Drug · Biological
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
41
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Not applicable Interventional Results available

BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder

NCT02657486
View directory record Official record
Conditions
Bladder Cancer, Non-Muscle-Invasive Urothelial Carcinoma
Interventions
BGJ398
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 28, 2026, 4:52 AM EDT
Terminated Phase 2 Interventional Results available

Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)

NCT04871529
View directory record Official record
Conditions
Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Infiltrating Renal Pelvis and Ureter Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8
Interventions
Therapeutic Conventional Surgery, Avelumab, Gemcitabine Hydrochloride, Carboplatin
Procedure · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
92
States / cities
Aurora, Colorado • Highlands Ranch, Colorado • Orlando, Florida + 70 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2024 · Synced Sep 28, 2026, 4:52 AM EDT